

## N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GORFIEN et al.

Appl. No. 09/028,514

Filed: February 23, 1998

For: Seri

Serum-Free Mammalian Cell

Culture Medium, and Uses

Thereof

Confirmation No.: 4800

Art Unit: 1651

Examiner: Ware, D.

Atty. Docket: 0942.4110002/RWE/FRC

July

## Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated March 26, 2004, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;

09/30/2004 DWILLIA4 00000001 (C) Starting on a separate sheet, the Remarks.

01 FC:1202

648.00 DA

FEE VALUE ACCOUNTABILITY		
BEPOSIT ACCOUNT NO.		
19	4500	
FEE	VALUE FURNISHED	$\langle \gamma \rangle$
1200	648 4	
	-	

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham

Attorney for Applicants Registration No. 50,437

Date: SEPT. 20, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

299104\_1.DOC